Reviewing Daxor (NASDAQ:DXR) & Fresenius SE & Co. (OTCMKTS:FSNUY)

Fresenius SE & Co. (OTCMKTS:FSNUY) and Daxor (NASDAQ:DXR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Insider & Institutional Ownership

1.3% of Daxor shares are held by institutional investors. 59.5% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Fresenius SE & Co. and Daxor”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fresenius SE & Co.	$23.63 billion	N/A	$509.67 million	$0.53	25.81
Daxor	N/A	N/A	N/A	N/A	N/A

Fresenius SE & Co. has higher revenue and earnings than Daxor.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Fresenius SE & Co. and Daxor, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fresenius SE & Co.	0	0	2	1	3.33
Daxor	0	1	1	0	2.50

Daxor has a consensus price target of $25.00, indicating a potential upside of 81.03%. Given Daxor’s higher possible upside, analysts plainly believe Daxor is more favorable than Fresenius SE & Co..

Profitability

This table compares Fresenius SE & Co. and Daxor’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fresenius SE & Co.	5.09%	9.33%	4.31%
Daxor	N/A	N/A	N/A

Volatility & Risk

Fresenius SE & Co. has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Daxor has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500.

Summary

Fresenius SE & Co. beats Daxor on 8 of the 11 factors compared between the two stocks.

About Fresenius SE & Co.

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.